| First Author | Abdoli A | Year | 2022 |
| Journal | bioRxiv | Mgi Jnum | J:321881 |
| Mgi Id | MGI:7256363 | Doi | 10.1101/2022.02.11.480131 |
| Citation | Abdoli A, et al. (2022) Omicron-based vaccine candidate elicits potent neutralizing antibodies in the animal model. bioRxiv |
| abstractText | The B.1.1.529 (Omicron) variant of SARS-Co V-2 with multiple novel mutations has reduced the neutralization potential of vaccinated individuals'' sera. World Health Organization has suggested that a vaccination strategy based on repeated booster doses is unlikely to be sustainable. The objective of this com1nenta1y was to investigate the safety and neutralizing antibody induction of the Omicron-based SARS-Co V-2 vaccine candidate, BIVI-Covlran Plus, against the Omicron variant on mice and guinea pig models. After isolation and characterization, the Omicron variant underwent chemical inactivation, purification, and was then fonnulated with alum adjuvant. A full human dose of BIVI-Covlran Plus was injected intraperitoneally to five fe11ale mice and two 1 Guinea pigs for abnonnal toxicity reactions evaluation and pathologic investigations. For potency evaluation, four groups of ten 111ice received two doses of BIVI-Covlran Plus or phosphate-buffered-saline at 7-day and 14-day intervals. The conventional virus-neutralizing test was conducted on sera acquired from vaccinated mice groups seven days after the second injection. There was no evidence of abnonnal clinical symptoms macroscopic or microscopic tissue alterations among the animal models. In all samples from the study group that received two doses of BIVI-Covlran Plus at a 7-day interval, the sera at 2::1/32 times dilution would neutralize the Omicron variant SARS-Co V-2. Similarly, the sera of all samples from the study group, which received two doses of BIVI-Covlran Plus at a 14- day interval, at 2::1/64 times dilution, would neutralize the Omicron variant SARSÂCo V-2. Moreover, six out of ten (60%) of the samples m this group would neutralize the Omicron variant of SARS-CoV-2 at 1/128 times dilution. CPE fonnation was observed in all samples from the control group, and no neutralizing activity was detected at any sera dilutions. BIVI-Covlran Plus was well-tolerated m the animal models, and no safety concerns were raised. Moreover, the vaccme candidate elicited protective neutralization against the Omicron variant. Future reports will focus on the use of the updated vaccme as a booster dose and the potency of the vaccine candidate on other SARS-CoV-2 variants. Keywords: Vaccine; Vi1us Neutralisation Test; Neutralizing antibody; Omicron variant; SARSÂCoV-2. |
